Biocon-Mylan Prime Pegfilgrastim Market Expansion
US Approves Biocon’s sBLA for New Pegfilgrastim Facility
Executive Summary
Biocon-Mylan’s sBLA approval for pegfilgrastim made at a new Indian site gets FDA go-ahead, facilitating a "multi-fold" scale up in capacity. But it will be interesting to watch how impactful this could be on market dynamics in the US, where more competition has arrived.
You may also be interested in...
Biocon Biologics Gets True North Investment
Private equity group True North continues to back the Biocon group and is picking up a minority stake in Biocon Biologics in a deal that values the subsidiary at $3bn. Separately, another subsidiary, Biocon Biosphere, has also been set up as part of efforts to unlock the full potential of the business.
Biocon Rings In 2020 With Gusto, PE Investment In Biologics Arm
Private equity group True North continues to back the Biocon group and is picking up a minority stake in Biocon Biologics in a deal that values the subsidiary at $3bn. Separately, another subsidiary, Biocon Biosphere, has also been set up as part of efforts to unlock the full potential of the business.
Sandoz Is Satisfied With US Pegfilgrastim Start
Initial market signals from Sandoz’ US launch of its Ziextenzo pegfilgrastim biosimilar are promising, global Biopharmaceuticals head Pierre Bourdage told Generics Bulletin.
Need a specific report? 1000+ reports available
Buy Reports